A list of 20 largest U.S. healthcare mergers and acquisitions announced in 2012, ranked by completed or pending deal's price. Source: Modern Healthcare's 2012 Healthcare M&A Watch series; WNS Global Services. Published Jan. 28, 2013, p. 42.

Read the full story: http://bit.ly/VzsvW6

Source: ModernHealthcare.com

Related Content

December 21st 2024

Health Equity & Access Weekly Roundup: December 21, 2024

Giuliana Grossi

The Center on Health Equity & Access provides news and expert insights on research, health policy, and the impact of social determinants on health.

December 19th 2024

Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma

Giuliana Grossi

Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.

FDA website | Image credit: Postmodern Studio – stock.adobe.com

December 20th 2024

FDA Rejects Sotagliflozin for Type 1 Diabetes; Lexicon Shifts Focus

Hayden E. Klein

The FDA issued a complete response letter for sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

December 20th 2024

FDA Approves Encorafenib With Cetuximab and mFOLFOX6 for Metastatic CRC

Julia Bonavitacola

Patients with the BRAF V600E mutation and metastatic colorectal cancer (CRC) can be treated with a combination of encorafenib with cetuximab and mFOLFOX6.

AJMC Q&A with Ian Neeland, MD | Background image credit: ipopba - stock.adobe.com

December 20th 2024

Team-Based CINEMA Program Targets SDOH and Precision Care in Diabetes

Hayden E. Klein

Ian Neeland, MD, discusses the CINEMA program's impact on addressing social determinants of health (SDOH) in Ohio and the importance of precision risk tests to reduce cardiovascular metabolic disease risk.

Related Content

December 21st 2024

Health Equity & Access Weekly Roundup: December 21, 2024

Giuliana Grossi

The Center on Health Equity & Access provides news and expert insights on research, health policy, and the impact of social determinants on health.

December 19th 2024

Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma

Giuliana Grossi

December 20th 2024

FDA Rejects Sotagliflozin for Type 1 Diabetes; Lexicon Shifts Focus

Hayden E. Klein

The FDA issued a complete response letter for sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

December 20th 2024

FDA Approves Encorafenib With Cetuximab and mFOLFOX6 for Metastatic CRC

Julia Bonavitacola

Patients with the BRAF V600E mutation and metastatic colorectal cancer (CRC) can be treated with a combination of encorafenib with cetuximab and mFOLFOX6.

December 20th 2024

Team-Based CINEMA Program Targets SDOH and Precision Care in Diabetes

Hayden E. Klein

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions